Anna Lübking (Former)
1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
(
- Contribution to journal › Article
- 2016
-
Mark
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
(
- Contribution to journal › Article
- 2015
-
Mark
Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.
(
- Contribution to journal › Article
- 2014
-
Mark
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
(
- Contribution to journal › Letter
- 2009
-
Mark
Donor lymphocyte infusion as therapy for persistent pure red cell aplasia following major ABO-incompatible stem cell transplantation
2009) 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation In Bone Marrow Transplantation 43. p.373-373(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Permissive roles of hematopoietin and cytokine tyrosine kinase receptors in early T cell development
(
- Contribution to journal › Article
-
Mark
FLT3 ligand and not TSLP is the key regulator of IL-7-independent B-1 and B-2 B Lymphopoiesis.
(
- Contribution to journal › Article